Whole blood viscosity and antiplatelet therapy
Paper
Nwose, E. U.. 2015. "Whole blood viscosity and antiplatelet therapy." Western NSW Health Research Network (WHRN) Scientific Symposium 2015. Orange, Australia 01 - 01 Jan 2015 Australia.
| Paper/Presentation Title | Whole blood viscosity and antiplatelet therapy |
|---|---|
| Presentation Type | Paper |
| Authors | Nwose, E. U. |
| Year | 2015 |
| Place of Publication | Australia |
| Web Address (URL) of Conference Proceedings | https://whrnnetwork.wordpress.com/ |
| Conference/Event | Western NSW Health Research Network (WHRN) Scientific Symposium 2015 |
| Event Details | Western NSW Health Research Network (WHRN) Scientific Symposium 2015 Delivery In person Event Date 01 to end of 01 Jan 2015 Event Location Orange, Australia |
| Abstract | Background & aim: Whole blood viscosity (WBV) is under-utilized and presumed as too sensitive and non-specific. This series on WBV issues aimed to elucidate the sensitivity, specificity and usefulness of the lab parameter in clinical practice. Particular interest was whether WBV is more specific or too sensitive for antiplatelet indication/contraindication. Method: Using 10-yrs archived clinical pathology data from South West Pathology, WBV was derived from HCT and TP. Extrapolation chart and reference values were developed. Association of and/or changes in WBV level with aceytl-salicyclate, CRP, D-dimer, ESR, FOB, homocysteine, INR, leucocytosis, leukapheresis, and platelet levels were determined. Results: Findings are hereby presented. Interesting findings include lower WBV levels being significantly associated with higher INR and blood acetyl-salicylate levels. WBV is not sensitive like CRP or ESR, but a very specific marker for stasis. Implications: WBV attenuates the efficacy of antiplatelet agents. WBV can be assessed and monitored for treated with the therapy. This is akin to INR monitoring of warfarin. There are issues relating to bleeding complications, non-responsiveness, resistance and treatment failure of antiplatelet. It is pertinent to separate the first (bleeding complications) from the other three; especially in terms of (i) medication prior to testing for resistance, responsiveness or treatment failure; versus (ii) testing prior to medication whether a patient would be at risk of bleeding. If the limitation has been test methodology, it is imperative to propagate the availability of a logarithmic chart method, especially the fact that it is akin or alternative to INR and that WBV can be derived for anybody who has result for FBC and LFT. Invited collaborations: Imput is being sought from researchers to recruit and assess patients. The current proposal is to do clinical observational prospective studies. For instance, whether 1. clients who fail to benefit from aspirin have familial factor in WBV 2. assessment of WBV in smokers will improve patient education and counselling towards withdrawal from smoking 3. prospective determination of bleeding or thrombotic risks will be associated with low or high WBV respectively 4. knowledge of the WBV logarithmic chart will improve assessment in rural community clinics and health facilities Outcome: The results will translate the value of WBV in cardiovascular medicine for better understanding and use in clinical practice |
| Contains Sensitive Content | Does not contain sensitive content |
| ANZSRC Field of Research 2020 | 420605. Preventative health care |
| Public Notes | There are no files associated with this item. |
| Byline Affiliations | Charles Sturt University |
Permalink -
https://research.usq.edu.au/item/z1y8q/whole-blood-viscosity-and-antiplatelet-therapy
46
total views0
total downloads1
views this month0
downloads this month